<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03571282</url>
  </required_header>
  <id_info>
    <org_study_id>2018KYPJ081</org_study_id>
    <nct_id>NCT03571282</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of Intravitreal Conbercept for Exudative Circumscribed Choroidal Haemangioma</brief_title>
  <official_title>Safety and Effectiveness Study of Intravitreal Conbercept Injection for Exudative Circumscribed Choroidal Haemangioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective clinical trial aims to evaluate the safety and effectiveness study of
      intravitreal conbercept injection for exudative circumscribed choroidal haemangioma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective clinical trial aims to evaluate the safety and effectiveness study of
      intravitreal conbercept injection for exudative circumscribed choroidal haemangioma: (1)To
      evaluate therapeutic effect (including both anatomical and functional responses to
      intravitreal conbercept injection) of intravitreal conbercept injectionfor exudative
      circumscribed choroidal haemangioma; (2)To evaluate the safety (including side effects of the
      eye as well as side effects of system) of intravitreal conbercept injection for exudative
      circumscribed choroidal haemangioma.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">June 6, 2018</start_date>
  <completion_date type="Anticipated">June 6, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 6, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best-corrected visual acuity</measure>
    <time_frame>half a year</time_frame>
    <description>change of best corrected visual acuity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Central foveal thickness</measure>
    <time_frame>half a year</time_frame>
    <description>change of central foveal thickness</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Circumscribed Choroidal Haemangioma</condition>
  <arm_group>
    <arm_group_label>treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients in the treatment group receive three monthly intravitreal injection of conbercept followed by PRN rescue treatments such as intravitreal injection of conbercept, laser photocoagulation (when outside the macular) or photodynamic therapy (when in the macular).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>conbercept</intervention_name>
    <description>After three monthly injections of conbercept, if no effects was seen in the patients, the patients will receive rescue treatments such as photodynamic therapy (in the macular) or laser photocoagulation (outside the macular).</description>
    <arm_group_label>treatment group</arm_group_label>
    <other_name>photodynamic therapy</other_name>
    <other_name>laser photocoagulation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1) patients with circumscribed choroidal haemangioma who was diagnosed using
             ophthalmoscopy, fluorescein/indocyanine green angiography, and ultrasonography; 2)
             presence of reduced visual acuity or metamorphopsia; and 3) subretinal fluid involving
             the fovea.

        Exclusion Criteria:

          -  patients with abnormal liver function test results, liver disease, porphyria, or
             previous treatment for circumscribed choroidal haemangioma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chenjin Jin, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongshan Ophthalmic Center, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kunbei Lai, ph.D.</last_name>
    <phone>8602087331366</phone>
    <email>laikb@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Ophthalmic Center, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiawei Wang</last_name>
      <phone>020-87331359</phone>
    </contact>
    <contact_backup>
      <last_name>Chenjin Jin</last_name>
      <phone>13302209900</phone>
    </contact_backup>
    <investigator>
      <last_name>Chenjin Jin</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kunbei Lai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 16, 2018</study_first_submitted>
  <study_first_submitted_qc>June 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2018</study_first_posted>
  <last_update_submitted>June 16, 2018</last_update_submitted>
  <last_update_submitted_qc>June 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Jin Chen-jin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>conbercept</keyword>
  <keyword>circumscribed choroidal haemangioma</keyword>
  <keyword>safety</keyword>
  <keyword>effectiveness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemangioma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

